Barchart on MSN2d
This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback